Messages in brief

News

COVID-19: Erinnerung an Risiken von Chloroquin und Hydroxychloroquin

messages in brief | 29/05/2020
Vorteilhafte Wirkung nicht belegt, aber Hinweise auf gravierende Nebenwirkungen
COVID-19: Erinnerung an Risiken von Chloroquin und Hydroxychloroquin Read more
News

COVID-19: Nebenwirkungsmeldungen

messages in brief | 30/04/2020
Only available in German
COVID-19: Nebenwirkungsmeldungen Read more
News

COVID-19: Warnung vor Risiko schwerwiegender Nebenwirkungen von Chloroquin und Hydroxychloroquin

messages in brief | 24/04/2020
Anwendung soll nur im Rahmen klinischer Studien oder valider Behandlungs-Protokolle stattfinden. Alle Nebenwirkungen sollen gemeldet werden.
COVID-19: Warnung vor Risiko schwerwiegender Nebenwirkungen von Chloroquin und Hydroxychloroquin Read more
News

COVID-19: Regulatory flexibility

messages in brief | 22/04/2020
Recent information about regulatory flexibility during the corona pandemic can be found here on the website of the BASG.
COVID-19: Regulatory flexibility Read more
News

EU Recommendations for the Seasonal Influenza Vaccine Composition for the Season 2020/2021

messages in brief | 22/04/2020
The EMA adopted the new recommendations for the composition of seasonal influenza vaccines for the season 2020/2021 (published 1 April 2020).
EU Recommendations for the Seasonal Influenza Vaccine Composition for the Season 2020/2021 Read more
News

Best possible supply of drugs for COVID 19 therapy

messages in brief | 20/04/2020
Central contact points in each federal state survey needs and coordinate distribution
Best possible supply of drugs for COVID 19 therapy Read more
News

New practice for sodium in the product information

messages in brief | 17/04/2020
In the EMA document "Compilation of QRD decisions on stylistic matters in product information" a new, Europe-wide harmonised practice for oral/parenteral medicinal products containing less than 1 mmol sodium per dose was published. In section 2 of the SmPC, there is no need to declare sodium, neither qualitatively nor quantitatively for oral/parenteral medicinal products containing less than 1 mmol sodium per dose. Section 3 of the labelling there is no need to declare sodium for oral medicinal products containing less than 1 mmol of sodium per dose.
New practice for sodium in the product information Read more
News

COVID-19: Warnung vor falscher Anwendung von Chloroquin

messages in brief | 02/04/2020
Chloroquin und Hydroxychloroquin dürfen gegen Corona-Virus nur in klinischen Studien oder Notfallprogrammen verwendet werden
COVID-19: Warnung vor falscher Anwendung von Chloroquin Read more
Email

Further inquiry note